Wednesday, April 22, 2026

UnitedHealthcare will eliminate prior authorization requirements for most medical services for non-urgent care delivered by in-network providers in rural areas, effective immediately. The policy change is part of an initiative to improve access to care. Rural clinics with UHC contracts should audit current authorization queues and instruct staff to stop submitting PAs for newly affected services, though policies for drugs, medical devices, and out-of-network services remain unchanged. Review UHC's provider portal for the official service list.

CMS published its proposed rule on interoperability and prior authorization for drugs in the Federal Register on April 14. The rule would require Medicare Advantage, Medicaid managed care, and Marketplace plans to implement a standard electronic PA process for Part D drugs. This builds on existing CMS regulations for medical services. The 60-day comment period closes June 13, 2026. Billing teams should track this rule's finalization, as it will mandate specific data exchange standards and could reduce manual follow-up for pharmacy benefit authorizations.

A CMS program piloting AI for prior authorization decisions, the WISE-R pilot, is reportedly causing significant delays in care for Medicare beneficiaries in Washington state. Hospitals report the automated system is more restrictive and slower than human review, prompting Senator Patty Murray to call for a pause and investigation. The program is a test case for broader AI integration into Medicare Advantage review processes. Billing managers should monitor this issue closely; widespread adoption of restrictive AI models could increase appeal volumes and create new bottlenecks.

CMS and the FDA announced the RAPID Coverage Pathway on April 22, a joint program designed to fast-track Medicare coverage for FDA-designated breakthrough medical devices. The goal is to reduce the lag between FDA approval and Medicare reimbursement, which historically has been years. For practices, this means certain new technologies, like advanced cardiac devices or neurostimulators, could become billable under Medicare sooner after market entry. The agencies will identify qualifying devices and establish parallel review processes. This changes the coverage landscape for specialists adopting cutting-edge tech, though the first devices under the pathway are not yet named.